Summary of protocol
EudraCT number: 2009-015012-18

Title	A prospective, randomized, open, multicentre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. Phase IV.
Primary endpoint	Proportion of patients who successfully reached the maintenance dose.
Study design	Multicentre, open, randomized, parallel group study.
Number of patients	30 patients
Main inclusion criteria	1. The subject aged > 18 years. 2. The subject suffering from IgE-mediated seasonal allergic rhinoconjunctivitis with or without mild asthma caused by grass pollen, documented by skin prick test (diameter > 3mm), or a positive provocation test for grass pollen, or specific serum IgE-test for grass pollen.
Exclusion criteria	1. The subject suffering from severe asthma or emphysema. 2. The subject treated with any specific immunotherapy during the previous 3 years for a period longer than three months. 3. The subject suffering from severe acute or chronic diseases.
Treatment	Therapy will cover a period of 16 weeks (conventional group) or 15 weeks (rush group).
Sponsor	HAL Allergy GmbH